1. Home
  2. CAST vs INDP Comparison

CAST vs INDP Comparison

Compare CAST & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FreeCast Inc. Class A Common Stock

CAST

FreeCast Inc. Class A Common Stock

N/A

Current Price

$1.25

Market Cap

162.3M

Sector

Technology

ML Signal

N/A

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$1.23

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CAST
INDP
Founded
2011
2000
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
171.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
CAST
INDP
Price
$1.25
$1.23
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$6.00
N/A
AVG Volume (30 Days)
448.6K
83.3K
Earning Date
06-26-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.50
$0.92
52 Week High
$12.20
$8.57

Technical Indicators

Market Signals
Indicator
CAST
INDP
Relative Strength Index (RSI) 33.75 30.28
Support Level $1.10 $0.92
Resistance Level $1.99 $3.05
Average True Range (ATR) 0.23 0.26
MACD -0.06 -0.10
Stochastic Oscillator 8.23 3.46

Price Performance

Historical Comparison
CAST
INDP

About CAST FreeCast Inc. Class A Common Stock

FreeCast Inc is a streaming technology company that provides platform-as-a-service solutions for television and digital video distribution. Its platform infrastructure supports telecom operators, internet service providers, broadcasters, municipalities, utilities, brands, and device manufacturers in deploying and managing digital media and streaming services.

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

Share on Social Networks: